• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Spyre Therapeutics (SYRE) Reports RA Trial Results, Is The Stock Overvalued?

    Simply Wall St·09/06/2026 09:25:13
    语音播报

    Spyre Therapeutics (SYRE) drew investor attention after reporting topline data from the rheumatoid arthritis sub study of its Phase 2 SKYWAY trial. The results confirmed TL1A proof of mechanism, although the company has decided not to prioritize SPY072 in RA.

    Spyre Therapeutics’ latest RA update comes after a sharp run in the stock, with a 1-year total shareholder return of 423.41% and a very large 3-year total shareholder return. However, the 30-day share price return of 15.18% in decline suggests some recent momentum cooling from earlier gains.

    Spot fresh momentum stories beyond Spyre Therapeutics by scanning a curated group of 18 high quality undiscovered gems that share strong fundamentals and potential catalysts.

    Bulls point to Spyre Therapeutics’ TL1A proof of mechanism and large multi asset pipeline, while bears focus on zero revenue, ongoing losses and a cooling share price. Which side does the current valuation appear to favor next?

    Preferred Price-to-Book of 8.2x for Spyre Therapeutics: Is it justified?

    Spyre Therapeutics closed at $88.98, and the stock is being valued at a P/B ratio of 8.2x. That sits below a peer group average of 11.7x, yet it is well above the broader US Biotechs industry average of 2.5x.

    The P/B ratio compares a company’s market value to its book value, which is essentially net assets on the balance sheet. For a clinical stage biotech like Spyre Therapeutics that currently reports zero revenue and a net loss of $150.213m, investors are often paying more for the potential of the pipeline than the current accounting equity.

    An 8.2x P/B suggests the market is placing a high value on Spyre Therapeutics’ IBD and rheumatic disease portfolio, including assets like SPY001, SPY002, SPY072 and its combination programs. At the same time, the lower P/B versus the 11.7x peer average signals investors are not assigning the very highest premium relative to similar companies, even though the stock’s 1 year total shareholder return has exceeded both the US Biotechs industry and the broader US market.

    The contrast with the sector level is stark. Compared with the wider US Biotechs industry average P/B of 2.5x, Spyre Therapeutics trades on a materially richer multiple, which indicates the market is pricing in a stronger asset outlook or execution than the typical biotech stock.

    Result: Price-to-book of 8.2x (OVERVALUED)

    However, Spyre Therapeutics still carries key risks, including zero current revenue and a recent 30 day share price decline of 15.18%, which could pressure sentiment.

    Find out about the key risks to this Spyre Therapeutics narrative.

    Next Steps

    With sentiment around Spyre Therapeutics split between promise and risk, it makes sense to move quickly and test the numbers for yourself using the 1 key reward and 5 important warning signs.

    Looking for more investment ideas beyond Spyre Therapeutics?

    If Spyre Therapeutics has your attention, do not stop here. Use these focused idea lists to pressure test your thinking and uncover fresh opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.